TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04133675

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella
Description: The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham BTL Emsella
Description: Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).
Study: NCT04334096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality of life pathway
Description: The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
Study: NCT04608201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour
Description: Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of NICOTINE Transdermal patch
Description: Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
Study: NCT04536506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Therapy
Description: Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vojta technique
Description: Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
Study: NCT01589601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual heart failure care
Description: Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary palliative care
Description: Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
Study: NCT04006119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: * intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veledimex
Description: 20mg/day 15 oral daily doses of veledimex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: Infusion every 3 weeks (350mg)
Study: NCT00199485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angelica Sinensis
Description: Angelica Sinensis / placebo
Study: NCT04633616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Patient-Provider Communication
Description: Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Tailored Patient-Provider Communication
Description: Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
Study: NCT03578809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: MEDI6012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: MEDI6012

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02474654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: 15mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine
Description: 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15mcg
Study: NCT04510740

Intervention type: OTHER
Intervention: Physician's choice according to patient's needs.
Description: Routine care as per site standard.

Intervention type: OTHER
Intervention: Physician's choice according to patient's needs.
Description: Routine care as per site standard.
Study: NCT03719300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inodiftagene vixteplasmid
Description: BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks
Study: NCT01384045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health promotion outreach
Description: Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
Study: NCT02768246

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BVGA
Description: The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BVGA
Description: The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask
Description: Classic face mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask
Description: Classic face mask
Study: NCT02919696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT02261792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24 hours Trendelenburg position
Description: Trendelenburg position
Study: NCT04113720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine hydrochloride
Description: levobupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride + Dexmedetomidine
Description: Levobupivacaine plus Dexmedetomidine
Study: NCT03225599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranial Osteopathic Manipulative Medicine
Description: The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position
Study: NCT02815410

Intervention type: DRUG
Group type: OTHER
Intervention: levetiracetam
Description: Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
Study: NCT03318900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study: NCT02261792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours bed rest
Description: 24 hours bed rest after EBP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBP
Description: Autologous Epidural Blood Patch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBP
Description: Autologous Epidural Blood Patch
Study: NCT00909688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01248819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 60 mg
Description: Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
Study: NCT03318900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD8-Positive T-Lymphocyte
Description: Given IV
Study: NCT01248819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 100 mg
Description: Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
Study: NCT03579719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
Study: NCT02565394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro Break with Dynamic Exercise Activities
Description: Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
Study: NCT00576745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl Suture
Description: A 4-0 vicryl suture will be used to close the subcuticular layer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M TM S Surgical Skin Closure System
Description: These steri-strips will be applied to close the skin in this cohort of patients
Study: NCT03318900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study: NCT02474654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15mcg
Study: NCT02856698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Dose use according to the product technical sheet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Dose use according to the product technical sheet
Study: NCT00776724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere , Epirubicin
Description: Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
Description: Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8.
Study: NCT02122432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teledermatology
Description: General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?
Study: NCT02029170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early weightbearing
Description: Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-weightbearing
Description: Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
Study: NCT02140242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: study part 1 - dose daunorubicin
Description: standard induction dose of daunorubicin 60 mg/m2 on days 3-5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: induction cycles
Description: single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induction cycles
Description: single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
Study: NCT02474654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epimorphine
Description: 150mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epimorphine
Description: 150mcg
Study: NCT04162509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR app
Description: Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
Study: NCT05181306

Intervention type: PROCEDURE
Intervention: Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy
Description: Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.

Intervention type: PROCEDURE
Intervention: Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy
Description: Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study: NCT00471640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 4 days 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: 4 days 5 mg
Study: NCT02492594

Intervention type: OTHER
Intervention: Peripheral blood sampling
Description: Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~* at the start of neutropenic fever~* after 24 hours~* after 48 hours~* before the start of antimycotic therapy, if pertinent~* at the end of antimycotic therapy, if pertinent

Intervention type: OTHER
Intervention: Peripheral blood sampling
Description: Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~* at the start of neutropenic fever~* after 24 hours~* after 48 hours~* before the start of antimycotic therapy, if pertinent~* at the end of antimycotic therapy, if pertinent
Study: NCT02474654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epimorphine
Description: 150mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epimorphine
Description: 150mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.3 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 30ml
Study: NCT02224833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Systematic review of treatments:~Identification of reasons for PPI.~* Determination of recommended pharmacotherapeutic alternatives.~* Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP.
Study: NCT02474654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 30ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 100 ml
Study: NCT03866460

Intervention type: DIAGNOSTIC_TEST
Intervention: Distortion product otoacoustic emission measurement (DPOAE)
Description: Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
Study: NCT03953417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta-burst treatment
Description: All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left DLPFC using the MagPRo stimulator.